Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen-receptor Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02273752
What this trial is testing

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerGastrinomaGlucagonoma+16 more
Emory University 2
Not applicableEnded earlyNCT05068726
What this trial is testing

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
GE Healthcare 51
Testing effectiveness (Phase 2)UnknownNCT04669587
What this trial is testing

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

Who this might be right for
Estrogen Receptor-PositiveHER2-NegativeLocally Advanced Breast Cancer+1 more
EnhancedBio USA Inc. 106
Testing effectiveness (Phase 2)Ended earlyNCT02202746
What this trial is testing

Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerMBC+5 more
Clovis Oncology, Inc. 178
Not applicableStudy completedNCT00115505
What this trial is testing

Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

Who this might be right for
Breast Carcinoma
Alliance for Clinical Trials in Oncology 307
Early research (Phase 1)Study completedNCT01344031
What this trial is testing

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveInvasive Breast CarcinomaRecurrent Breast Carcinoma+1 more
National Cancer Institute (NCI) 31
Early research (Phase 1)Study completedNCT02123823
What this trial is testing

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Who this might be right for
Neoplasms
Boehringer Ingelheim 164
Testing effectiveness (Phase 2)Study completedNCT02291913
What this trial is testing

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
SCRI Development Innovations, LLC 48
Testing effectiveness (Phase 2)Ended earlyNCT04675827
What this trial is testing

De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Who this might be right for
HER2-positive Breast CancerER-Negative Breast CancerPR-Negative Breast Cancer+1 more
Jules Bordet Institute 139
Not applicableEnded earlyNCT02823262
What this trial is testing

A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older

Who this might be right for
Breast CancerEstrogen Receptor Positive Breast CancerNode-negative Breast Cancer+1 more
Beth Israel Deaconess Medical Center 65
Large-scale testing (Phase 3)Study completedNCT01740427
What this trial is testing

Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Who this might be right for
Breast Neoplasms
Pfizer 666
Testing effectiveness (Phase 2)Study completedNCT00546156
What this trial is testing

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Who this might be right for
Breast Cancer
Ian E. Krop, MD, PhD 104
Testing effectiveness (Phase 2)Looking for participantsNCT06525766
What this trial is testing

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen-receptor-positive Breast CancerMetastatic HER2-Negative Breast Carcinoma+1 more
Mayo Clinic 35
Not applicableNot Yet RecruitingNCT07387861
What this trial is testing

PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study

Who this might be right for
Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Assiut University 70
Testing effectiveness (Phase 2)UnknownNCT05927779
What this trial is testing

Study of TFX06 in Women With Advanced Breast Cancer.

Who this might be right for
ER+, HER2- Advanced Breast CancerMetastatic Breast Cancer
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. 74
Not applicableEnded earlyNCT02149173
What this trial is testing

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

Who this might be right for
Estrogen Receptor PositiveRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
University of Washington 29
Testing effectiveness (Phase 2)Study completedNCT02077569
What this trial is testing

AKT Inhibitor in Oestrogen Positive Breast Cancer

Who this might be right for
Invasive Breast Cancer
University of Nottingham 48
Early research (Phase 1)Active Not RecruitingNCT03332797
What this trial is testing

GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 181
Large-scale testing (Phase 3)WithdrawnNCT03081234
What this trial is testing

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT00417885
What this trial is testing

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer 6
Next Page